News – Page 605 – Endpoints News

Junshi and Coherus plan to hustle the latest PD-1 to the FDA after an upbeat PhIII assessment

4 years ago

As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — ...

4 years ago

Genentech's tocilizumab shortage due to Covid-19 now hits CAR-T recipients, with FDA offering alternatives to help

4 years ago

Covid-19 roundup: French regulators not ready to give molnupiravir the OK; Brii claims China’s first antibody is ...

4 years ago

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act

4 years ago

Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal

4 years ago

Qiming-backed CANbridge gets its Hong Kong IPO as Nasdaq slowdown prompts renewed market analysis

4 years ago

Pfizer scoops up Arena and its S1P drug in $6.7B buyout — chasing Bristol Myers and capping a lengthy biotech ...

4 years ago

ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging ...

4 years ago

ASH: Tessa Therapeutics' next-gen cell therapy clears four patients' tumors in early study

4 years ago

Op-ed: What we’re watching closely as an unusual #ASH21 kicks off in Atlanta

4 years ago

ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio

4 years ago

ASH: A cell therapy startup with roots in Irv Weissman's lab nearly wipes out a chronic side effect in early trials

4 years ago

ASH: Gilead's Kite unveils more data on Yescarta's win in second-line lymphoma patients, setting up battle for SOC

4 years ago

ASH: With Yescarta leading in earlier-line lymphoma, Bristol Myers keeps the heat on with full data for Breyanzi

4 years ago

ASH: Servier unveils full dataset for Tibsovo in specific AML mutations, and the FDA appears a stone's throw away

4 years ago

Endpoints honors 20 women supercharging drug R&D; Omicron is a 'stress test' for the next pandemic; Roche and ...

4 years ago

Moderna's flu data offer a clear lesson: mRNA isn't magic

4 years ago

After investing in their Series B, Lilly bags a license for a batch of metabolic candidates

4 years ago

CVS takes a swing at Bristol Myers and Pfizer, excluding coverage of their megablockbuster Eliquis in 2022

4 years ago

The latest healthcare SPAC comes in at $200M with a laser focus on artificial intelligence

4 years ago

Roche offers an upbeat two-plus-year look at its anti-TIGIT combo therapy — but will two deaths hurt its chances?

4 years ago

Dekkers-founded investment firm Novalis LifeSciences raises $300M for second fund and adds to the team

4 years ago

Oversight Committee unleashes scathing drug pricing report as Senate preps to vote on allowing Medicare negotiations

4 years ago

First page Previous page 602 603 604605606 607 608 Next page Last page